# BEHOLD-1 (NCT06431594)

> A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06431594
- Phase: PHASE1
- Status: RECRUITING
- Sponsor: GlaxoSmithKline
- Conditions: Solid Tumors; Neoplasms
- Interventions: Mocertatug rezetecan
- Enrollment: 675
- Primary outcome: Part 1: Number of participants with dose limiting toxicity (DLT)
- Primary outcome: Part 2-Confirmed Objective Response Rate (ORR) assessed by investigator

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3
- Podcasts: 2
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=behold-1-nct06431594